Lactiga™ is an award-winning, venture-backed biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk to create the next generation of anti-infectives that can battle even the world’s most dangerous pathogens.
Developing novel antibodies for mucosal infections in rare immunodeficiencies
Signup for updates below:
In the news
25-90% of individuals with primary immunodeficiencies will eventually develop complications.
Recurrent ear infections, sinusitis, pneumonia, and diarrhea are the most common symptoms in patients with Selective IgA Deficiency (SIgAD).
The prevalence of SIgAD is over 1 in 700, accounting for millions worldwide.
Common Variable Immune Deficiency (CVID)affects over
1 in 50,000 people and is classified as a rare disease.
What conditions are we focusing on?
What are maternal antibodies?
They are large proteins, derived from a mother’s breastmilk, that bind and neutralize pathogens.
Has this been done?
The novelty of our work is reflected in our granted US, Canadian and Japanese patents.
The search for better
treatment options is on
If you’re a patient suffering from an antibody deficiency, we’d love to hear from you — your journey motivates our work. If you’re interested in investment or partnership opportunities, let’s have a discussion.
© Lactiga
